

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERO
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

DATE MAILED: 09/01/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/620,514	07/16/2003	Ricardo M. Attar	D0287 NP	3956	
23914	7590 09/01/2006		EXAMINER		
LOUIS J. WILLE			HAMA, JOANNE		
BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT		ART UNIT	PAPER NUMBER		
POBOX 4000	) NI 08543 4000		1632		

Please find below and/or attached an Office communication concerning this application or proceeding.

# Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)	
	10/620,514	ATTAR ET AL.	
	Examiner	Art Unit	
	Joanne Hama, Ph.D.	1632	

	Joanne Hama, Ph.D.	1632				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED 15 August 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.						
<ol> <li>The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:</li> <li>The period for reply expiresmonths from the mailing</li> </ol>	ring replies: (1) an amendment, aff tice of Appeal (with appeal fee) in o e with 37 CFR 1.114. The reply mo	idavit, or other eviden compliance with 37 Cl	ce, which FR 41.31; or (3)			
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (TWO MONTHS OF THE FINAL REJECTION. See MPEP 70	dvisory Action, or (2) the date set forth tter than SIX MONTHS from the mailin b). ONLY CHECK BOX (b) WHEN THE 16.07(f).	g date of the final rejection in the second section in the second	on. ILED WITHIN			
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount hortened statutory period for reply orig than three months after the mailing da	of the fee. The appropri inally set in the final Office	ate extension fee ce action; or (2) as			
<ol> <li>The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter a Notice of Appeal has been filed, any reply must be filed AMENDMENTS</li> </ol>	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	is of the date of e appeal. Since			
3. The proposed amendment(s) filed after a final rejection, I  (a) They raise new issues that would require further cor  (b) They raise the issue of new matter (see NOTE belor  (c) They are not deemed to place the application in bet	nsideration and/or search (see NO w);	TE below);				
appeal; and/or (d) ☐ They present additional claims without canceling a on NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally rej	ected claims.				
<ul> <li>4.  The amendments are not in compliance with 37 CFR 1.12</li> <li>5.  Applicant's reply has overcome the following rejection(s)</li> <li>6.  Newly proposed or amended claim(s) would be all</li> </ul>	<u>112, 2nd</u> .	·	•			
non-allowable claim(s).  7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided the status of the claim(s) is (or will be) as follows:  Claim(s) allowed: none.  Claim(s) objected to: none.  Claim(s) rejected: 1-13 and 18-20.  Claim(s) withdrawn from consideration: none.		II be entered and an e	explanation of			
<ul> <li>AFFIDAVIT OR OTHER EVIDENCE</li> <li>8. ☐ The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ul>	t before or on the date of filing a N I sufficient reasons why the affidav	otice of Appeal will <u>no</u> rit or other evidence is	t be entered necessary and			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary.  10. The affidavit or other evidence filed after the date of filing entered by the showing a good and sufficient reasons why it is necessary.	vercome <u>all</u> rejections under apper and was not earlier presented. S	al and/or appellant fai ee 37 CFR 41.33(d)(1	ls to provide a			
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER		•				
<ul> <li>11.  The request for reconsideration has been considered bu see attached.</li> <li>12.  Note the attached information Displaceure Statement(a) (1)</li> </ul>			ice because:			
<ul><li>12. ☐ Note the attached Information Disclosure Statement(s).</li><li>13. ☐ Other:</li></ul>	F 10/35/06 01 F 10-1449) Paper N	vo(s)				

Art Unit: 1632

Applicant filed a response to the Final Action of June 16, 2006 on August 15, 2006. Claims 1-4, 7, 11, 12, 13, 20 are amended. Claims 14-17 are cancelled.

Claims 1-13, 18-20 are under consideration.

#### Withdrawn Rejection

35 U.S.C. § 112, 2<sup>nd</sup> parag.

Applicant's arguments, see page 6 of Applicant's response, filed August 15, 2006, with respect to the rejection of claim 7 have been fully considered and are persuasive. Applicant has amended the claim. The rejection of claim 7 has been withdrawn.

### New/Maintained Rejections

35 U.S.C. § 101

Applicant's arguments filed August 15, 2006 have been fully considered but they are not persuasive. Applicant indicates that the claims have been amended to indicate that the claimed mouse exhibits enhanced expression of androgen receptor relative to a wild type mouse. Applicant indicates that the transgenic mice provide a model system to monitor activity of androgen receptor in different organs and tissues. As such, Applicant asserts that the claimed invention has utility because it can be used to study the mouse tissue's selective activity of pharmacological agents by inhibition or activation of androgen receptor in different organs and tissues (Applicant's response, page 5-6). In response, Applicant's response is not persuasive because as indicated in the Office

Action of December 29, 2005, pages 4-5, studying the effects of the transgene's overexpression in a mouse is a general, rather than a specific utility of the claimed mouse. The Office Action also indicates that the transgenic mice described in the specification's Examples do not have any phenotype. The use of a transgenic mouse with no phenotype is not readily apparent. Thus, the rejection remains.

# 35 U.S.C. § 112, 1st parag.

Applicant's arguments filed August 15, 2006 have been fully considered but they are not persuasive. Applicant indicates that the specification enables one of skill in the art to make and (in view of the arguments above concerning the rejection under 35 U.S.C. § 101) use the claimed invention (Applicant's response, page 6). In response, as discussed above in the 35 U.S.C. § 101 rejection, the claimed mice have no readily apparent use and thus, the rejection of these claims <u>remain</u>.

### 35 U.S.C. § 112, 2<sup>nd</sup> parag.

The "transgenic non-human mammal" of claim 18 lacks antecedent basis. The scope of claim 1 is to a mouse and is not as broad as any non-human mammal.

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joanne Hama, Ph.D. whose telephone number is 571-

Application/Control Number: 10/620,514

Art Unit: 1632

272-2911. The examiner can normally be reached Monday through Thursday and alternate Fridays from 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, Ph.D. can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file

Application/Control Number: 10/620,514

Art Unit: 1632

folder(s) as well as general patent information available to the public. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

JH

ANNE M. WEHBE PH.D PRIMARY EXAMINER Page 5